BioWorld Asia

July 19, 2006

Actelion, Roche Sign $630M Autoimmunity Product Deal

Shrugging off recent disappointments in the clinic, Actelion AG signed what is likely to be one of the landmark licensing deals in European biotechnology in 2006. (BioWorld International) Read More

DeCode Stock Sale To Raise $30M For Multidrug Pipeline

Motility Control Proteins Might Play Part In Pancreatic Cancer

Crucell Shares Fall After Aerugen Program Ended

ProStrakan Secures Deal, Raises £11M In Placement

Nasdaq In Lead, But Potential LSE Merger Raises Questions

Cellectis, Lexicon Genetics Exchange Rights To Patents

Devices In Past, Medisys Now Complete As Investing Firm

Advanced Therapies Under Scrutiny At EU Parliament

Astion Brings In DKK50M For Dermatology Pipeline

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...